Research progress on screening prostate cancer in the PSA＂gray zone＂and PI-RADS 3 lesions.
- Author:
You MA
1
;
Cheng YANG
1
Author Information
1. Department of Urology, The First Affiliated Hospital of Anhui Medical University/Research Institute of Urology, Anhui Medical University/Key Laboratory of Anhui Province for Urological and Andrological Diseases Research and Medical Transformation, Hefei, Anhui 230022, China.
- Publication Type:English Abstract
- Keywords:
prostate cancer； radiomics； prostate specific antigen； PI-RADS 3 lesions； magnetic resonance imaging
- MeSH:
Humans;
Male;
Prostatic Neoplasms/diagnosis*;
Prostate-Specific Antigen/blood*;
Magnetic Resonance Imaging;
Early Detection of Cancer;
Biopsy;
Prostate/pathology*
- From:
National Journal of Andrology
2025;31(6):547-551
- CountryChina
- Language:Chinese
-
Abstract:
Prostate cancer is a common tumor of the male genitourinary system, with its incidence continuously increasing. Early accurate diagnosis is crucial for treatment and prognosis. PSA and MRI are important methods for screening and diagnosis of prostate cancer. However, there is still controversy over whether patients with PSA levels between 4-10 μg/L and PI-RADS score of 3 need to undergo prostate biopsy. Radiomics technology provides a new approach for the early and accurate diagnosis of prostate cancer by mining and analyzing medical image information in a high throughput, which helps to reduce unnecessary biopsies. This article reviews the research progress of MRI radiomics in the screening of prostate cancer in the "gray zone" of PSA and PI-RADS score of 3, aiming to improve diagnostic accuracy and provide references for future research in the field of radiomics.
